Most Read Articles
Pearl Toh, Yesterday
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
4 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 6 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.

Point-of-care HPV DNA screening comparable to cervical cancer biopsy

Rachel Soon
Medical Writer
10 Oct 2018
Cervical cancer is a leading cause of cancer mortality for women in 44 countries. [Image source: WHO 2018]

Newer molecular tests for high-risk human papillomavirus (hrHPV) may provide a cost-effective means for cervical cancer screening for low-to-middle income countries (LMICs), with results comparable to cervical biopsies.

In a series of clinical performance validation studies comprising over 1,700 HIV-positive women from Zambia and South Africa, it was found that compact point-of-care (POC) molecular assays could detect hrHPV with a higher degree of sensitivity compared to conventional methods of visual inspection with acetic acid (VIA) or digital cervicography (DC).

Speaking at the recent World Cancer Congress 2018 in Kuala Lumpur, Dr Carla Chibwesha, assistant professor of obstetrics and gynaecology at University of North Carolina at Chapel Hill, presented the results of three studies from her team, intended as proof-of-concept before larger trials.

The first study, conducted in Zambia, enrolled 200 HIV-positive women who were screened with Xpert HPV (a DNA assay), OncoE6 (a protein-based assay), VIA, DC and a histological standard for cervical intraepithelial neoplasia grade 2 or more (CIN2+) as a baseline.

Compared to the standard, the DNA assay provided greater sensitivity (88 percent; 95 percent confidence interval, CI 71–97) than the other three methods (protein assay: 31percent, 95 percent CI 16–50; VIA: 48 percent, 95 percent CI 30–67; DC: 59 percent, 95 percent CI 41–76). However, the assay had only a moderate level of specificity in comparison (60 percent versus 99, 92 and 88 percent respectively). [J Low Genit Tract Dis 2016;20(3):218–223]

Subsequently, a second study enrolling 1,161 HIV-positive women was conducted in South Africa to compare Xpert HPV and Hybrid Capture II to histological standard (CIN2+). Both Xpert HPV and Hybrid Capture II shared similar sensitivity and specificity compared to baseline (HC2 sensitivity 92 percent, specificity 51 percent; Xpert HPV 88 percent, specificity 48 percent). [Papillomavirus Res 2016;2:56–60]

The third study, also in South Africa, enrolled 350 HIV-positive women and examined the agreement in hrHPV detection between self- and provider-collected samples. It was found that the positive hrHPV detection rate in self-collected samples (45%) was similar to provider-collected (37%) with an agreement of 83% (kappa 0.65, 95 percent CI 0.52–0.77). [SAHIVSOC 2016, abstract 208]

Currently, VIA and DC are widely used in many LMICs to facilitate affordable access to cervical cancer screening. According to Chibwesha, nurses in Zambian clinics perform DC simply using store-bought digital cameras, televisions and computer screens to provide magnification of the cervix, simultaneously facilitating patient education.

“However, we’ve known for at least 10 years now that HPV screening predicts cervical disease better than visual methods or cytology, so when point-of-care analysers such as Xpert HPV started to come on the market, we began thinking about how molecular testing could be integrated into cervical screening,” said Chibwesha.

Future directions for research include a larger trial planned to evaluate optimal triage of HPV screening methods, as well as integration of HPV screening into Zambian treatment models to reach a “test-and-treat” approach, said Chibwesha. Mobile health solutions that enable screening results to be communicated directly to patients by SMS are also an area of interest.

“Despite the availability of vaccinations and multiple screening modalities, pre-cancer treatment modalities and good treatments available for invasive cervical cancer, it remains the leading cause of death in 44 countries,” said Chibwesha. “Global disparities in cervical cancer incidence and mortality are largely the result of inequities in access to healthcare for women and girls.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, Yesterday
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
4 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 6 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.